AstraZeneca PLCAZN:LSE

4,327.5
7.00 / 0.16%
2.02m
34.19%
0.3968
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Oct 24 2014 16:36 BST.

About the company

16.20bn1.26bn199251.50k
Revenue in GBP (TTM)Net income in GBPIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
AstraZeneca PLC
2 Kingdom Street, Paddington
LONDONW2 6BD
United Kingdom
GBR
Phone+44 20 7604 8000Fax+44 20 7604 8151Websitehttp://www.astrazeneca.com/
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca's products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Mergers & acquisitions

Acquired company
Deal status
DateAZN:LSE since
announced
Transaction
value
Forest Laboratories IncRumoured04 Dec 2013+23.41%--
Data delayed at least 15 minutes, as of Oct 24 2014 16:36 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Shire PLC
3.34bn1.17bn23.00bn5.34k19.606.1116.746.891.991.175.656.380.55561.445.44624,93919.4618.9526.1618.9585.5486.6635.0220.660.9149107.800.147811.228.9910.3076.1952.24-9.665915.00
AstraZeneca plc
16.20bn1.26bn54.81bn51.50k43.343.9913.653.381.001.0012.8710.890.46152.423.44314,5483.6118.205.0318.2079.7881.497.8222.440.8557.190.313651.95-8.0864-4.0415-59.0385-15.9705-12.61556.43
GlaxoSmithKline plc
24.81bn4.75bn68.48bn99.82k14.5311.1911.482.760.9720.9725.081.260.61321.834.69248,51512.2016.7318.0816.7369.5072.3119.9016.950.77079.900.720878.570.2801.7120.833.39-3.84136.47
Sanofi SA
26.09bn3.26bn88.70bn112.13k27.352.1616.313.403.103.1024.9439.350.3531.604.49--4.515.875.315.8767.1270.2212.7913.470.956719.200.222368.29-7.37272.94-23.9926-0.0805-2.7364.94
Novo Nordisk A/S
8.90bn2.74bn60.18bn40.23k27.6219.2319.856.769.769.7631.6514.021.321.387.482,216,57340.5141.5265.7941.5283.3081.6030.7926.160.9902--0.01144.357.1112.9017.5121.1612.35-5.5913
Data as of Oct 24 2014. Currency figures normalised to AstraZeneca PLC's reporting currency: .
Data delayed at least 20 minutes, as of Oct 25 2014 00:06 BST.

Institutional shareholders

HolderShares% Held
BlackRock Investment Management (UK) Ltd.
as of 23 May 2014
71.47m5.66%
Wellington Management Co. LLP
as of 22 May 2014
64.92m5.14%
Legal & General Investment Management Ltd.
as of 22 May 2014
43.43m3.44%
Invesco Asset Management Ltd.
as of 22 May 2014
37.55m2.97%
State Street Global Advisors Ltd.
as of 23 May 2014
35.43m2.81%
Aberdeen Asset Managers Ltd.
as of 21 May 2014
30.08m2.38%
Norges Bank Investment Management
as of 28 Apr 2014
27.80m2.20%
Capital Research & Management Co. (World Investors)
as of 23 May 2014
27.73m2.20%
Schroder Investment Management Ltd.
as of 22 May 2014
24.20m1.92%
SAFE Investment Co., Ltd.
as of 28 Apr 2014
22.35m1.77%
30.49%
Per cent of shares
held by top holders
Data from 31 Dec 2013 - 03 Oct 2014Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.